source
- Biogen's tau antisense therapy shows 38% slower decline in 2-year Alzheimer extension studyBiogen presented new data from the open‑label extension of its phase 2 Celia trial at the CTAD 2026 conference. The update focused on the tau‑targeting antisense oligonucleotide, diranersen, admini…
- Priavoid’s Alzheimer’s drug misses primary goal in phase 2 trial, shows later cognitive benefit signalGerman biotech Priavoid reported that its oral all-D-peptide candidate, PRI-002, did not achieve the primary efficacy endpoint in the phase 2 PRImus-AD study of patients with mild cognitive impairm…